Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pengshi Shengjing is a Traditional Chinese Medicine (TCM) formula developed by the Shanghai Hospital of Traditional Chinese Medicine, specifically based on the clinical experience of Dr. Peng Peiyuan. It is primarily indicated for the treatment of male infertility conditions, including asthenospermia (low sperm motility) and oligospermia (low sperm count). The formula is designed to tonify the kidney essence and strengthen the reproductive system. Pharmacologically, it is thought to improve sperm quality by modulating the hypothalamic-pituitary-gonadal (HPG) axis, enhancing mitochondrial function in spermatozoa, and reducing oxidative stress in the seminal plasma. It is typically administered as an oral granule preparation and is registered as a hospital preparation in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pengshi shengjing.